Scott T.  Garrett net worth and biography

Scott Garrett Biography and Net Worth

Director of HCW Biologics

Scott Garrett has served on our board of directors since May 2021. He is currently a Senior Operating Partner at Water Street Healthcare Partners (“Water Street”). Prior to joining Water Street in 2011, Mr. Garrett served as Chairman, President and Chief Executive Officer of Beckman Coulter, Inc., a leading biomedical company, from 2008 to 2011. Mr. Garrett joined Beckman Coulter, Inc. in 2002 as President, Clinical Diagnostics Division and was promoted to President and Chief Operating Officer in 2003. In January 2005, he became Chief Executive Officer and in 2008, added the position of Chairman.

Prior to that, Mr. Garrett served as Vice Chairman and Interim Chief Executive Officer of Kendro Laboratory Products from 1999 to 2001; Chairman, President and Chief Executive Officer of Dade Behring, a leading diagnostics company, from 1994 to 1998; and Operating Partner of Garrett Capital, First Chicago Equity Capital from 1998 to 2002. Mr. Garrett began his career at American Hospital Supply Corporation and continued there after the company was acquired by Baxter International, ultimately serving as Chief Executive of Baxter International’s global laboratory business, Baxter Diagnostics from 1992 to 1994.

Mr. Garrett serves on the board of Immucor, Inc. and Hologic, Inc. and the boards of companies in which Water Street has an ownership interest, including Orgentec Diagnostics and Pathnostics, Inc. He also serves on the board of the Advanced Medical Technology Association Diagnostics and its Executive Committee. Mr. Garrett received his B.S. degree in mechanical engineering from Valparaiso University and an M.B.A. from the Lake Forest Graduate School of Management. He also completed the Executive Management program at Stanford University Graduate School of Business.

What is Scott T. Garrett's net worth?

The estimated net worth of Scott T. Garrett is at least $70.96 thousand as of July 29th, 2026. Mr. Garrett owns 41,644 shares of HCW Biologics stock worth more than $70,961 as of October 9th. This net worth approximation does not reflect any other assets that Mr. Garrett may own. Learn More about Scott T. Garrett's net worth.

How do I contact Scott T. Garrett?

The corporate mailing address for Mr. Garrett and other HCW Biologics executives is 2929 N Commerce Pkwy, Miramar, FL, 33025. HCW Biologics can also be reached via phone at 954-842-2024 and via email at [email protected]. Learn More on Scott T. Garrett's contact information.

Has Scott T. Garrett been buying or selling shares of HCW Biologics?

Scott T. Garrett has not been actively trading shares of HCW Biologics during the last quarter. Most recently, on Wednesday, July 29th, Scott T. Garrett bought 7,736 shares of HCW Biologics stock. The stock was acquired at an average cost of $2.58 per share, with a total value of $19,958.88. Following the completion of the transaction, the director now directly owns 41,644 shares of the company's stock, valued at $107,441.52. Learn More on Scott T. Garrett's trading history.

Who are HCW Biologics' active insiders?

HCW Biologics' insider roster includes Lee Flowers (SVP), Scott Garrett (Director), and Jin-An Jiao (VP). Learn More on HCW Biologics' active insiders.

Are insiders buying or selling shares of HCW Biologics?

During the last year, HCW Biologics insiders bought shares 4 times. They purchased a total of 47,500 shares worth more than $310,874.64. The most recent insider tranaction occured on July, 29th when SVP Lee Flowers bought 7,736 shares worth more than $19,958.88. Insiders at HCW Biologics own 9.1% of the company. Learn More about insider trades at HCW Biologics.

Information on this page was last updated on 7/29/2026.

Scott T. Garrett Insider Trading History at HCW Biologics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/29/2026Buy7,736$2.58$19,958.8841,644View SEC Filing Icon  
5/22/2026Buy29,656$8.46$250,889.7633,906View SEC Filing Icon  
See Full Table

Scott T. Garrett Buying and Selling Activity at HCW Biologics

This chart shows Scott T. Garrett's buying and selling at HCW Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HCW Biologics Company Overview

HCW Biologics logo
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Read More

Today's Range

Now: $1.64
Low: $1.52
High: $1.73

50 Day Range

MA: $2.48
Low: $1.53
High: $3.60

2 Week Range

Now: $1.64
Low: $1.50
High: $27.57

Volume

55,908 shs

Average Volume

1,247,161 shs

Market Capitalization

$3.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.41